Clinical Trials on Fallopian Tube Serous Adenocarcinoma

Total 1346 results

Kazia Therapeutics Limited

Completed

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Australia
Duke University

Completed

The Treatment Preferences of Women Diagnosed With Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
University College, London
Boehringer Ingelheim

Completed

Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (METRO-BIBF)

Ovarian Cancer | Fallopian Tube Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Completed

Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life

Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Vaginal Cancer | Peritoneal Cancer | Uterine Cancer

United States
Eli Lilly and Company

Completed

A Study of Chemotherapy Treatment for Patients With Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Italy, United States, Russian Federation
Amgen

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Austria, Belgium, Italy, Netherlands, Spain, Canada, Denmark, Germany, Korea, Republic of, Russian Federation, Hong Kong, Greece, Japan
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer (S0009)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada
University of Pennsylvania
National Cancer Institute (NCI); Alliance for Cancer Gene Therapy; OvaCure Fundation and other collaborators

Terminated

MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Ovarian Cancer | Fallopian Tube Cancer

United States
Mayo Clinic

Completed

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States, Canada
Cairo University

Completed

Hysteroscopic Versus Laparoscopic Tubal Occlusion in Cases of Hydrosalpinx and Planning for IVF

Tubal Obstruction

Egypt
Mahidol University

Completed

Antispasmodic Drug for Diagnosis Proximal Tubal Occlusion on Hysterosalpingography

Tubal Obstruction

Thailand
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Clovis Oncology, Inc.

Active, not recruiting

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Linda R Duska
Novartis

Completed

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
NCIC Clinical Trials Group

Completed

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
M.D. Anderson Cancer Center
The Blanton Davis Ovarian Cancer Research Program

Unknown

Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Eli Lilly and Company

Completed

Study of Ramucirumab in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States, United Kingdom
Medical University Innsbruck
European Commission

Terminated

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

France, Austria, Belgium, Germany
UConn Health
Genentech, Inc.

Terminated

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Stage 4 Cancer | Stage 3 Cancer

United States
David O'Malley
Genentech, Inc.

Unknown

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | No Prior Chemotherapy

United States
MEI Pharma, Inc.

Completed

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Australia
Merrimack Pharmaceuticals
Sanofi

Completed

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States
The Catholic University of Korea
Korean Cancer Study Group

Completed

Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Korea, Republic of
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
AGO Study Group

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

Germany
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Imunon
Break Through Cancer Foundation

Recruiting

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Shanghai Gynecologic Oncology Group
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Obstetrics... and other collaborators

Not yet recruiting

Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
Green3Bio, Inc.

Suspended

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

Ovarian Tumors

United States
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

China
H. Lee Moffitt Cancer Center and Research Institute
The V Foundation for Cancer Research; Kay Yow Cancer Fund

Completed

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer

Peritoneal Diseases | Ovarian Diseases | Fallopian Tube Diseases | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Ronald Buckanovich

Completed

Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma

United States
Jason D. Wright
Genentech, Inc.

Completed

Neoadjuvant Therapy for Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
ImmunoGen, Inc.
Gynecologic Oncology Group

Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
Royal Surrey County Hospital NHS Foundation Trust

Unknown

Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival (MIRRORS)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Ovarian Neoplasm | Ovarian Neoplasm Epithelial

United Kingdom
Abramson Cancer Center of the University of Pennsylvania
Ovarian Cancer Research Center

Terminated

Autologous OC-L Vaccine and Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Primary Ovarian Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Merck Sharp & Dohme LLC; Brigham and Women's...

Terminated

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
The University of Texas Health Science Center at...

Completed

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (ONTAK)

Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
NYU Langone Health
Genentech, Inc.

Completed

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
Women and Infants Hospital of Rhode Island
Amgen

Terminated

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (PanGem)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Medical Research Council
European Organisation for Research and Treatment of Cancer - EORTC

Completed

Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Spain, Belgium, France, Netherlands, Austria, United Kingdom, Italy, South Africa, Portugal, Ireland
AstraZeneca

Completed

ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States

Clinical Trials on Fallopian Tube Serous Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations